T1	p 44 68	cholangiopancreatography
T2	p 167 178	anesthetist
T3	p 261 292	cholangiopancreatography ( ERCP
T4	p 431 441	PCS ) with
T5	p 459 496	anesthetist-controlled sedation ( ACS
T6	p 630 705	included 281 adults in 301 procedures . The PCS group ( n = 101 ) delivered
T7	p 1187 1204	n = 0 ; PCS n = 4
T8	p 1217 1220	n =
T9	p 1258 1282	sedated patients ( OAA/S
T10	i 44 68	cholangiopancreatography
T11	i 104 144	patient-controlled propofol sedation and
T12	i 161 180	nurse anesthetist .
T13	i 250 285	retrograde cholangiopancreatography
T14	i 288 294	ERCP )
T15	i 401 496	patient-controlled sedation ( PCS ) with propofol , nurse anesthetist-controlled sedation ( ACS
T16	i 541 550	midazolam
T17	i 721 747	5 mg of propofol according
T18	i 822 830	propofol
T19	i 992 1001	midazolam
T20	i 1162 1180	midazolam sedation
T21	i 1207 1216	midazolam
T22	i 1350 1359	midazolam
T23	i 1579 1587	propofol
T24	i 1603 1612	midazolam
T25	o 6 14	Sedation
T26	o 328 365	safety , ease of treatment , recovery
T27	o 368 371	and
T28	o 381 394	' experiences
T29	o 420 428	sedation
T30	o 766 774	sedation
T31	o 1084 1158	ease of the procedure and reduced the number of sedation failures compared
T32	o 1172 1180	sedation
T33	o 1258 1265	sedated
T34	o 1283 1288	level
T35	o 1291 1332	) , desaturation , and obstructed airways
T36	o 1369 1409	Time to full recovery ( Aldrete score ?9
T37	o 1461 1483	least fatigue and pain
T38	o 1661 1702	recovery , fewer respiratory events , and